Skip to main content

Published locations for RECIST underestimates benefit of pembrolizumab in subset of melanoma patients

Primary tabs

  • View
  • Get Stamp Tags
  • Published Locations

Breadcrumb

  1. Home
  3. RECIST underestimates benefit of pembrolizumab in subset of melanoma patients

User login

  • Reset your password
  • /content/recist-underestimates-benefit-pembrolizumab-subset-melanoma-patients
  • /edermatologynews/article/107161/melanoma/recist-underestimates-benefit-pembrolizumab-subset-melanoma
  • /oncologypractice/article/107161/melanoma/recist-underestimates-benefit-pembrolizumab-subset-melanoma
  • /hematology-oncology/article/107161/melanoma/recist-underestimates-benefit-pembrolizumab-subset
  • /dermatology/article/107161/melanoma/recist-underestimates-benefit-pembrolizumab-subset-melanoma